Development-stage biopharmaceutical company MannKind Corp. narrowed its first-quarter loss but still faces a very shaky financial and regulatory future, according to a Tuesday morning note from Baird analyst Thomas J. Russo.
The Valencia, Calif., company said Monday it lost $41.5 million, or 34 cents per share, compared to a loss of $44.7 million, or 40 cents per share, in the same quarter a year ago. MannKind ( MNKD - news - people )'s reported revenue of $50,000, compared with zero a year earlier.
